Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at D. Boral Capital

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $9.00 target price on the stock. D. Boral Capital’s price target indicates a potential upside of 234.57% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Stock Down 0.4 %

Shares of CTXR stock opened at $2.69 on Tuesday. The stock’s 50-day moving average price is $3.14 and its 200 day moving average price is $8.36. The stock has a market capitalization of $23.11 million, a PE ratio of -0.45 and a beta of 1.28. Citius Pharmaceuticals has a 52-week low of $2.44 and a 52-week high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). Analysts expect that Citius Pharmaceuticals will post -4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of large investors have recently modified their holdings of CTXR. Tower Research Capital LLC TRC grew its holdings in Citius Pharmaceuticals by 103.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock worth $33,000 after acquiring an additional 4,168 shares during the period. Fisher Asset Management LLC purchased a new stake in shares of Citius Pharmaceuticals during the 4th quarter worth $51,000. IFP Advisors Inc grew its stake in shares of Citius Pharmaceuticals by 21.2% during the 4th quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock worth $162,000 after purchasing an additional 7,083 shares during the period. Chelsea Counsel Co. increased its holdings in shares of Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock valued at $141,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Citius Pharmaceuticals in the third quarter valued at about $50,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.